mRNA Vaccine and Therapeutics Market Growth and Status Explored in a New Research Report 2035
The success of mRNA - based Covid-19 vaccines, coupled with an expanding product pipeline, has sparked innovation and progress of mRNA - based treatments across a wide spectrum of diseases.
The global mRNA vaccine and therapeutics market size for Covid-19 is estimated to be worth US$9 billion in 2024. Further, mRNA vaccine and therapeutics market size for other indications is projected to be US$1.99 billion by 2035, representing a CAGR of 16% during the forecast period from 2026 to 2035.
Presently, 21 companies that are engaged in the development of mRNA vaccine and therapeutics are based in North America. In this peer group, Moderna emerged as the most prominent player in this domain of pipeline strength, followed by Providence Therapeutics and IMMORNA. It is worth mentioning that Moderna is a large company with an extensive experience of over 10 years in developing mRNA-based drug candidates. The company has a robust mRNA drug pipeline, of which two mRNA-based drug has been marketed, namely Spikevax and TeenCOVE / KidCOVE. Spikevax (COVID-19 mRNA Vaccine) that targets COVID-19 infection in individuals with 18 years of age and above, received FDA approval in the US.
The remarkable efficacy of mRNA based COVID-19 vaccines has sparked innovation and progress in mRNA based treatments, expanding their potential expressions towards broad spectrum of diseases.
Providence Therapeutics, that emerged as another player, has a robust pipeline, with 11 drug candidates, intended for the treatment of infectious diseases and oncological disorders. Other mRNA vaccine and therapeutics developers based in North America, Arcturus Therapeutics, Turn Biotechnologies, Innovac Therapeutics and Strand Therapeutics.
More Than 345,000 Patients Have Been Recruited / Enrolled in Clinical Trials Registered For Various mRNA-Based Therapies, Across Different Geographies
We came across 178 clinical trials focused on mRNA vaccine and therapeutics that have been completed / ongoing in this domain.
We identified majority of the mRNA vaccine and therapeutics are being enclosed in lipid nanoparticles for delivery inside the cells. It is worth mentioning that lipid nanoparticles have proved to be a versatile mRNA drug delivery system by playing a significant role in transporting the mRNA to the target cells effectively. Other commonly employed delivery methods for the mRNA vaccine and therapeutics include lipopolyplex and liposomes systems.
majority of the mRNA vaccine and therapeutics intended for the treatment of infectious diseases are delivered primarily via intramuscular route (98%) whereas 57% mRNA-based therapies targeting oncological disorders are designed for intravenous administration.
The majority of the patients (45%) were enrolled in trial sites located in North America. Of these, 73% individuals were recruited in various hospitals / centers in the US. Additionally, Mexico emerged as the prominent location, in terms of number of patients enrolled, during the given period. In Europe, majority of the patients were enrolled in Germany (~30%).
Leading Players in mRNA Vaccine and Therapeutics Market
Examples of key companies engaged in the development of mRNA vaccine and mRNA therapeutics (which have also been profiled in this market report; the complete list of companies is available in the full report) include Arcturus Therapeutics, BioNTech, CureVac, Ethris, IMMORNA, Moderna, Providence Therapeutics, RNACure, Suzhou Abogen Biosciences and Turn Biotechnologies.
Distribution by Application Area -Covid-19 and Other Indications
Target Disease Indication -Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases
Geographical Regions (North America, Europe, Asia-Pacific, Latin America and Rest of the World)
In addition, Bill & Melinda Gates Foundation emerged as the most active investor (in terms of number of instances) in this domain having participated in seven funding instances.
mRNA Vaccine and Therapeutics: Market Sizing and Opportunity Analysis
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis